Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1799 results
November 2016
-
Featured NewsWhen innovation draws a new future for patient treatments
A recent summit explored how technological advances could impact patient care.
-
Featured NewsNovartis, Medikidz® and the COPD Foundation: a partnership of superhero proportions
We teamed up with Medikidz and the COPD Foundation to develop a creative way to explain COPD to children.
-
Media ReleaseNovartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancerPriority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared…
October 2016
-
Experimental treatment clears malaria infections in small clinical study
Compound offers a potential tool for fighting drug-resistant malaria parasites.
-
Media ReleaseNovartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology ProductBasel, October 31, 2016 - Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "…
-
Featured NewsNovartis dialogue to explore solutions to the rise of chronic diseases in the developing world
The event, called “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016, on the Novartis Campus in Basel, Switzerland and will also be webcast.
-
Media ReleaseNovartis a réalisé un troisième trimestre solide, les produits de croissance[1] ayant compensé l'expiration du brevet de Glivec; plusieurs résultats positifs concernant des blockbusters potentielsChiffre d'affaires net du T3 (-1% tcc[2] et USD) largement comparable au T3 2015 grâce à l'excellente performance des produits de croissance Gilenya (USD 790 millions, +15% tcc) a poursuivi sa…
-
Media ReleaseNovartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbustersQ3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301…
-
Media ReleaseNovartis erzielt im dritten Quartal solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust des Patents für Gleevec wettmachen; mehrere positive Daten für potenzielle BlockbusterDank starker Performance der Wachstumsprodukte bleibt der Nettoumsatz im dritten Quartal (-1% kWk[2] und USD) weitgehend unverändert gegenüber dem Vorjahreszeitraum Gilenya (USD 790 Millionen, +…
-
Media ReleaseAlcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meetingAlcon to host first live training program on the use of the CyPass® Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle…
-
The Evolution of a Scientist
A middle school student curious about science grows into a college-bound scientist.
-
Women in Science: Tania Small
Meet a Senior Medical Director at Novartis who is part of our new “Women in Science” series
Pagination
- ‹ Previous page
- 1
- …
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- …
- 150
- › Next page